Regeneron Pharmaceuticals Q3 2024 Update

TL;DR

Regeneron's Q3 2024 shows strong product sales & collaboration revenue growth vs. last year.

AI Summary

Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported significant product sales and collaboration revenues for the third quarter and the first nine months of 2024, showing growth compared to the same periods in 2023. Specific financial figures for these periods are detailed within the filing.

Why It Matters

This filing provides investors with the latest financial performance data for Regeneron, crucial for understanding the company's revenue generation and operational health in the pharmaceutical sector.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.

Key Numbers

• 2024-09-30 — Period End Date (Quarterly reporting period)
• 2023-12-31 — Previous Year End Date (Comparison point for annual data)
• 2024-07-01 to 2024-09-30 — Q3 2024 Product Sales Period (Specific timeframe for product revenue)
• 2023-07-01 to 2023-09-30 — Q3 2023 Product Sales Period (Specific timeframe for product revenue comparison)
• 2024-01-01 to 2024-09-30 — YTD 2024 Product Sales Period (Specific timeframe for year-to-date product revenue)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Filer
• 20240930 (date) — Period of Report
• 20241031 (date) — Filing Date
• 777 OLD SAW MILL RIVER ROAD (address) — Business Address
• TARRYTOWN (location) — City
• NY (location) — State
• 10591 (zip_code) — Business Zip Code
• 9148477000 (phone_number) — Business Phone

FAQ

Filing Documents

• regn-20240930.htm (10-Q) — 2191KB
• regn-ex_101x9302024x10q.htm (EX-10.1) — 23KB
• regn-ex_311x09302024x10q.htm (EX-31.1) — 12KB
• regn-ex_312x09302024x10q.htm (EX-31.2) — 12KB
• regn-ex_32x09302024.htm (EX-32) — 7KB
• 0001804220-24-000040.txt ( ) — 7886KB
• regn-20240930.xsd (EX-101.SCH) — 38KB
• regn-20240930_cal.xml (EX-101.CAL) — 63KB
• regn-20240930_def.xml (EX-101.DEF) — 235KB
• regn-20240930_lab.xml (EX-101.LAB) — 492KB
• regn-20240930_pre.xml (EX-101.PRE) — 365KB
• regn-20240930_htm.xml (XML) — 1202KB

Financial Statements (unaudited)

Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations and Comprehensive Income 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 47 Item 4.

Controls and Procedures

Controls and Procedures 48 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 48 Item 1A.

Risk Factors

Risk Factors 48 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 82 Item 5. Other Information 82 Item 6. Exhibits 83 SIGNATURE PAGE 84 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Ordspono ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," " Veloci-Bi ," " VelociGene ," " VelociHum ," " VelociMab ," " VelocImmune ," " VelociMouse ," " VelociSuite ," " VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions, except per share data) September 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 2,011.8 $ 2,730.0 Marketable securities 7,784.7 8,114.8 Accounts receivable, net 6,107.1 5,667.3 Inventories 3,018.0 2,580.5 Prepaid expenses and other current assets 412.0 386.6 Total current assets 19,333.6 19,479.2 Marketable securities 8,490.9 5,396.5 Property, plant, and equipment, net 4,439.2 4,146.4 Intangible assets, net 1,120.1 1,038.6 Deferred tax assets 3,015.1 2,575.4 Other noncurrent assets 1,043.0 444.1 Total assets $ 37,441.9 $ 33,080.2 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 497.3 $ 606.6 Accrued expenses and other current liabilities 2,536.5 2,357.9 Deferred revenue 627.2 458.9 Total current liabilities 3,661.0 3,423.4 Long-term debt 1,984.0 1,982.9 Finance lease liabilities 720.0 720.0 Deferred revenue 207.4 126.7 Other noncurrent liabilities 1,543.6 854.1 Total liabilities 8,116.0 7,107.1 Stockholders' equity: Preferred Stock, par value $ .01 per share; 30.0 shares authorized; shares issued and outstanding - no ne — — Class A Stock, convertible, par value $ .001 per share; 40.0 shares authorized; shares issued and outstanding - 1.8 in 2024 and 2023 — — Common Stock, par value $ .001 per share; 320.0 shares authorized; shares issued - 135.3 in 2024 and 133.1 in 2023 0.1 0.1 Additional paid-in capital 12,702.8 11,354.0 Retained earnings 30,755.2 27,260.3 Accumulated other comprehensive income (loss) 60.2 ( 80.9 ) Treasury Stock, at cost; 27.0 shares in 2024 and 25.5 shares in 2023 ( 14,192.4 ) ( 12,560.4 ) Total stockholders' equity 29,325.9 25,973.1 Total liabilities and stockholders' equity $ 37,441.9 $ 33,080.2 The accompanying notes are an integral part of the financial statements. 2 Table of Contents REGENERON PHARMACEU

View Full Filing

View this 10-Q filing on SEC EDGAR